B
14.48
0.58 (4.17%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Biohaven Ltd. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| BHVN | - | - | - | 191.77 |
| RCUS | - | - | - | 6.65 |
| ANRO | - | - | - | 4.45 |
| NUVB | - | - | - | 6.44 |
| DNA | - | - | - | 2.12 |
| ANVS | - | - | - | 16.34 |
AIStockmoo Score
| Value 35% | -0.2 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -0.2 |
| Timing 35% | 2.8 |
| AI Technical info | NA |
| Technical Oscillators info | 4.0 |
| Technical Moving Averages info | 1.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×0.79 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.9% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -0.9 |
| Final Score | 0.72 |
Select this tab to load the latest available analysis.
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.96% |
| % Held by Institutions | 90.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Infinitum Asset Management, Llc | 30 Jun 2026 | 6,250,000 |
| Royalty Pharma Sub-Manager, Llc | 30 Jun 2026 | 2,936,507 |
| Cormorant Asset Management, Lp | 30 Jun 2026 | 2,610,000 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |